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BET bromodomain inhibitors PFI-1 and JQ1 
are identified in an epigenetic compound 
screen to enhance C9ORF72 gene expression 
and shown to ameliorate C9ORF72-associated 
pathological and behavioral abnormalities 
in a C9ALS/FTD model
Esteban Quezada1, Claudio Cappelli1, Iván Diaz1, Nur Jury1, Nicholas Wightman2, Robert H. Brown Jr.2, 
Martín Montecino1,3* and Brigitte van Zundert1,2,4* 
Abstract 
Background: An intronic GGG GCC (G4C2) hexanucleotide repeat expansion (HRE) in the C9ORF72 gene is the most 
common cause of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), referred to as C9ALS/FTD. 
No cure or effective treatment exist for C9ALS/FTD. Three major molecular mechanisms have emerged to explain 
C9ALS/FTD disease mechanisms: (1) C9ORF72 loss-of-function through haploinsufficiency, (2) dipeptide repeat (DPR) 
proteins mediated toxicity by the translation of the repeat RNAs, and more controversial, (3) RNA-mediated toxic-
ity by bidirectional transcription of the repeats that form intranuclear RNA foci. Recent studies indicate a double-hit 
pathogenic mechanism in C9ALS/FTD, where reduced C9ORF72 protein levels lead to impaired clearance of toxic 
DPRs. Here we explored whether pharmacological compounds can revert these pathological hallmarks in vitro and 
cognitive impairment in a C9ALS/FTD mouse model (C9BAC). We specifically focused our study on small molecule 
inhibitors targeting chromatin-regulating proteins (epidrugs) with the goal of increasing C9ORF72 gene expression 
and reduce toxic DPRs.
Results: We generated luciferase reporter cell lines containing 10 (control) or ≥ 90 (mutant) G4C2 HRE located 
between exon 1a and 1b of the human C9ORF72 gene. In a screen of 14 different epidrugs targeting bromodomains, 
chromodomains and histone-modifying enzymes, we found that several bromodomain and extra-terminal domain 
(BET) inhibitors (BETi), including PFI-1 and JQ1, increased luciferase reporter activity. Using primary cortical cultures 
from C9BAC mice, we further found that PFI-1 treatment increased the expression of V1-V3 transcripts of the human 
mutant C9ORF72 gene, reduced poly(GP)-DPR inclusions but enhanced intranuclear RNA foci. We also tested whether 
JQ1, an BETi previously shown to reach the mouse brain by intraperitoneal (i.p.) injection, can revert behavioral 
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Background
Amyotrophic lateral sclerosis (ALS) and frontotemporal 
dementia (FTD) are two devastating, progressive neu-
rodegenerative diseases with clinically distinct entities. 
ALS, also known as Lou Gehrig’s disease, is a motoneu-
ron disease affecting spinal cord, brainstem and cranial 
motoneurons, leading to death by respiratory failure 
within 3–5  years of diagnosis [1]. The majority of ALS 
patients have the sporadic form of the disease (sALS), but 
about 10% of the cases have familial ALS (fALS), which 
is associated with pathogenic mutations in genes such 
as superoxide dismutase 1 (SOD1), transactive response 
DNA-binding protein 43 (TARDBP encoding TDP43), 
and C9ORF72, which is characterized by an intronic hex-
anucleotide expansion. FTD, the second most common 
cause of early dementia (< 65  years) after Alzheimer’s 
disease [2], is characterized by progressive deficits in 
behavior, language and executive functions due to a neu-
ronal atrophy in the frontal and temporal cortices [1, 3, 
4]. Despite these distinct clinical entities, ALS and FTD 
patients also can present clinical and histopathological 
overlaps and share similar genetic signatures, including 
pathogenic mutations in TARDBP and C9ORF72 [1, 2, 5–
7]. In fact, patients harboring mutations in C9ORF72 can 
suffer from ALS, FTD or a mixture of both, explaining 
the wide clinical diversity of both diseases. ALS and FTD 
have been classified as the extreme ends of the ALS/FTD 
spectrum; individuals carrying mutations in C9ORF72 
are collectively referred to as C9ALS/FTD patients. 
Currently, there is no cure and no effective treatments 
to halt, or reverse, the progression C9ALS/FTD, or for 
non-C9ORF72 related ALS patients, partly because of an 
incomplete understanding of the causative pathomecha-
nisms of these disorders.
Since the discovery that a hexanucleotide repeat 
expansion (HRE) composed of the GGG GCC  (G4C2) 
sequence within the first intron of the C9ORF72 gene 
is the most common cause of C9ALS/FTD [8, 9], major 
efforts have been undertaken to comprehend the 
underlying mechanism of this mutation (reviewed in 
[7, 10–14]). While the number of HRE is up to 25 in 
healthy subjects, C9ALS/FTD patients usually carry 
hundreds to thousands HRE in tandem in one of the 
alleles of the gene, forming higher-order DNA struc-
tures called G-quadruplexes [11, 12, 15, 16]. Three 
major pathogenic mechanisms have been implicated 
in C9ALS/FTD. First, the most widely accepted dis-
ease mechanism involves repeat associated non-ATG 
(RAN) translation of the sense and antisense C9ORF72 
transcripts leading to the accumulation of toxic dipep-
tide repeat (DPR) proteins that form neuronal inclu-
sions in the brains of C9ALS/FTD patients [17–21]. 
The five DPRs contain glycine (G), alanine (A), argi-
nine (R) and/or proline (P) residues produced from 
the repeat transcripts. Of the five DPRs, poly(GA) and 
poly(GR) are uniquely produced from the sense  (G4C2) 
transcripts, while poly(PA) and poly(PR) are uniquely 
generated from the antisense  (G2C4) transcripts; 
poly(GP) can be produced from both transcripts. 
Toxicity of DPRs is specifically high for arginine-con-
taining DPR proteins and involves many processes, 
including deficits in nucleocytoplasmic transport 
and RNA processing [11, 12]. Second, the sense and 
antisense transcripts generated by the bidirectional 
transcription of the expanded C9ORF72 gene form 
nuclear repeat-containing RNA inclusions, or RNA 
foci, a hallmark in C9ALS/FTD patient tissues [8, 19, 
22–25]. However, whether RNA foci are toxic [11] or 
neuroprotective under certain circumstances [26, 27] 
remains unclear. Third, C9ORF72 loss-of-function 
leads to decreased C9ORF72 mRNA and protein lev-
els in C9ALS/FTD patient tissues and derived cell 
lines [8, 9, 28–35]. Reduced C9ORF72 gene expression 
is related to epigenetic alterations at this locus, with 
an enrichment of several repressive histone modifica-
tions, including trimethylation of lysine 9 and 27 of 
histone H3 (H3K9me3, H3K27me3) as well as DNA 
methylation in the C9ORF72 gene promoter and/or 
HRE sequence [36–42]. Additionally, the generation of 
full length C9ORF72 transcripts is impaired by DNA 
G-quadruplexes that result in abortive transcription 
[12, 15, 16]. Loss of C9orf72 in worm and zebrafish 
models induces motoneuron death and motor deficits 
[43, 44]. While reduction or elimination of C9ORF72 
also can lead to neuronal dysfunction and death in 
human and mouse cultures [45], depletion of C9orf72 
abnormalities in C9BAC mice. Interestingly, it was found that JQ1 administration (daily i.p. administration for 7 days) 
rescued hippocampal-dependent cognitive deficits in C9BAC mice.
Conclusions: Our findings place BET bromodomain inhibitors as a potential therapy for C9ALS/FTD by ameliorating 
C9ORF72-associated pathological and behavioral abnormalities. Our finding that PFI-1 increases accumulation of intra-
nuclear RNA foci is in agreement with recent data in flies suggesting that nuclear RNA foci can be neuroprotective by 
sequestering repeat transcripts that result in toxic DPRs.
Keywords: C9ORF72, Epigenetics, BET inhibitors, DPR, RNA foci, Memory
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alone in mice does not lead to neurodegeneration or 
CNS behavioral changes [46–52]. These results indi-
cate that C9ORF72 loss-of-function by itself is not 
sufficient to drive neurodegeneration in mice [53]. 
Moreover, recent studies suggest a double-hit patho-
genic mechanism in C9ALS/FTD, where reduced 
C9ORF72 protein levels leads to autophagy deficits 
and hence impaired clearance of toxic DPRs [14, 54]. 
Together, these data indicate that increasing C9ORF72 
gene expression could subsequently reduce the pres-
ence of toxic DPRs.
Here, we addressed whether pharmacological com-
pounds can improve or even reverse the C9ALS/FTD 
disease phenotypes. We specifically focused our study 
on small molecules inhibiting chromatin-regulating 
proteins (epidrugs) to increase C9ORF72 gene expres-
sion and hence potentially ameliorate C9ORF72-asso-
ciated pathological  and behavioral abnormalities. A 
previous study by Zeier et  al. [42] used a semi-high-
throughput screen to identify siRNAs and small mol-
ecule inhibitors of epigenetic modifier proteins that 
increase the expression of C9ORF72 RNA in fibro-
blasts, lymphocytes and induced pluripotent stem 
cells (iPSC)-derived motoneurons from C9ALS 
patients. This study provides evidence that bromo-
domain and extra-terminal domain (BET) inhibitors 
(BETi), including JQ1 and I-BET151 (PFI-1 was not 
tested), as regulators of the C9ORF72 locus in C9ALS. 
BET proteins (BRD2, BRD3, BRD4 and BRDT) play a 
key role in transcription and chromatin remodeling 
(see discussion). In our study, we tested 14 selec-
tive small molecules that target and inhibit the activ-
ity of bromodomains as well as chromodomains and 
histone-modifying enzymes. To evaluate the effect of 
these epidrugs we took advantage of novel SH-SY5Y 
luciferase reporter cell lines comprising 10 (control) 
or ≥ 90 (mutant) G4C2 HRE. It was found that the 
bromodomain and BETi PFI-1 and JQ1 were the most 
effective epidrugs in enhancing the activity of the 
mutant human C9ORF72 gene. We also examined pri-
mary cortical neurons from a C9ALS/FTD transgenic 
mouse model, C9BAC, that carries a bacterial artifi-
cial chromosome (BAC) containing a fragment of the 
human C9ORF72 gene derived from a familial ALS/
FTD patient [55]. Treatment of these cells with PFI-1 
enhanced expression of the human mutant C9ORF72 
gene, increased accumulation of nuclear RNA foci 
and reduced poly(GP)-DPR inclusions. Finally, treat-
ment with JQ1 (daily i.p. administration for 7  days) 
reduced hippocampal-dependent cognitive impair-
ments in C9BAC mice. Together, our data demonstrate 
that BETi can increase C9ORF72 gene expression and 
reduce the presence of toxic DPRs in  vitro. In  vivo, 
these compounds can reduce memory deficits in a 
C9ALS/FTD mouse model.
Results
Bromodomain inhibitors enhance transcription 
of the human C9ORF72 gene stably integrated in SH‑SY5Y 
cells
To assess the effect of targeting different chromatin-reg-
ulators on the expression of the human C9ORF72 gene, 
we first generated an in vitro model of C9ALS/FTD that 
facilitates drug screenings. Specifically, we stably trans-
fected SH-SY5Y cells with a construct that contains part 
of the human C9ORF72 gene, including the promoter 
region (4  kb) and exons 1a through 2, cloned upstream 
of the luciferase reporter gene (Fig.  1a). Between exons 
1a and 1b, these constructs contain two different sizes 
of G4C2 repeat motifs: a control construct including 10 
repeats (SH-SY5Y WT) and a pathological version con-
taining 90 repeats (SH-SY5Y LE90) (Fig. 1a). As expected, 
the basal luciferase activity of SH-SY5Y LE90 cells was 
significantly reduced compared to the control line SH-
SY5Y WT (Fig.  1b). Our screening assay included 14 
selective small molecules that target and inhibit the activ-
ity of bromodomains, chromodomains and histone-mod-
ifying enzymes, including the histone methyltransferase 
EZH2, the histone demethylase LSD-1 and the histone 
acetyltransferase p300 (Fig.  1c). These epidrugs were 
selected because they target proteins that belong to prin-
cipal epigenetic regulatory pathways that control gene 
expression in a large number of biological systems under 
multiple physiological cues [56–58].
Details on these epidrugs, including their molecu-
lar structure, target proteins, and final concentrations 
used to treat the SH-SY5Y cells for 24  h are shown in 
Additional file 1: Table S1. Dose response curves (rang-
ing from 1 nM to 35 µM) were generated for each com-
pound (always freshly prepared). Optimal results for 
most of these epidrugs were reached when applied for 
24 h at a concentration of 5 µM. Exceptions were found 
for RXV208 (25  µM), OTX015 (2.5  µM) and GSK343 
(0.5  µM). At these selected concentrations, these com-
pounds induced the highest luciferase activity without 
causing any detectable cytotoxicity (not shown). As nec-
essary controls, SH-SY5Y cells were either untreated or 
treated with vehicle DMSO. The DMSO volume concen-
trations (v/v) ranged from 0.005% to 0.25% (see Methods) 
and did not induce cytotoxicity or changes in luciferase 
activity compared to untreated SH-SY5Y cells (Fig. 1c for 
0.5% DMSO and data not shown).
All the bromodomain-related inhibitors PFI-1, (+)-JQ1 
(henceforth, JQ1), RVX-208, GSK2801 and I-BET151 
enhanced the luciferase activity in SH-SY5Y LE90 cells, 
compared to the controls (Fig. 1c). PFI-1, JQ1, RVX-208 
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and I-BET151 are selective and potent BETi, whereas 
GSK2801 is a selective inhibitor of the bromodomain 
adjacent zinc finger (BAZ2) [59, 60]. Some bromodomain 
and BET inhibitors were also tested in a second disease 
model cell line containing 200 G4C2 repeats between 
exons 1a and 1b of the human C9ORF72 gene (SH-
SY5Y LE200); the proliferation rates of SH-SY5Y LE200 
cells were significantly lower compared to the SH-SY5Y 
LE90 cells and therefore used for selected epidrugs. As 
expected, SH-SY5Y LE200 cells also exhibited a strongly 
reduced basal luciferase activity compared to the control 
line SH-SY5Y WT (Additional file 1: Fig. S1A, B). In line 
with the results found in SH-SY5Y LE90 cells, we found 
that bromodomain inhibitors PFI-1, RVX-208, I-BET151 
significantly enhanced the luciferase activity in SH-SY5Y 
LE200 (Additional file  1: Fig. S1C). We also found that 
OTX015 (another BETi) did significant increase lucif-
erase activity in SH-SY5Y LE200 cells, while this epid-
rug was not effective in the SH-SY5Y LE90 cells (Fig. 1c; 
Additional file  1: Fig. S1C). Conversely, GSK2801 was 
Fig. 1 Bromodomain inhibitors enhance C9ORFF72 gene promoter-driven expression in the SH-SY5Y LE90 G4C2 reporter cell line. a Schematic 
representation of the two SH-SY5Y cell lines stably expressing a segment of the human C9ORF72 gene, including the promoter region and exons 
1a through 2, driving the expression of a luciferase reporter gene. Between exons 1a and 1b, increasing G4C2 hexanucleotide repeat expansions 
(red hexagons) were inserted: 10 (SH-SY5Y WT) or 90 (SH-SY5Y LE90). b Quantification of the basal luciferase activity in each cell line. Values 
were normalized to total protein concentration and displayed as relative luciferase unit (RLU). Bars represent mean ± S.E.M. ***P < 0.001 relative 
to SH-SY5Y WT cells, unpaired Student’s t-test (n = 3 independent experiments). c Quantification of luciferase activity at the SH-SY5Y LE90 cells 
following an incubation for 24 h with 14 selective small molecule inhibitors targeting bromodomains (green bars), histone methyltransferase EZH2 
(blue bars), chromodomains (brown bars), the histone demethylase LSD1 (red bar) and the histone acetyltransferase p300 (orange bar). As a control, 
SH-SY5Y LE90 cells were also treated with 0.05% (v/v) DMSO (white bar), the same concentration used as the vehicle for most of the epidrugs. 
Luciferase activity in the treated SH-SY5Y LE90 cells was normalized to untreated SH-SY5Y LE90 cells (black bar). Bars represent mean ± S.E.M. 
***P < 0.001 relative to DMSO, or ###P < 0.001 relative to Untreated, one-way ANOVA (n = 3 independent experiments)
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able to increase luciferase activity in the SH-SY5Y LE90 
cells, but not in the SH-SY5Y LE200 cells.
Using the SH-SY5Y LE90 cells, we also tested several 
inhibitors for chromodomains and the histone-modifying 
enzymes EZH2, LSD-1 and p300. Only the chromodo-
main inhibitor UNC669 and the EZH2 inhibitor GSK343 
significantly increased luciferase activity, while other 
epidrugs targeting similar domains/enzymes had no 
effect (Fig. 1c). Based on these results, we concluded that 
the BETi PFI-1 and JQ1 are the most potent chemical 
probes mediating increased transcription of the human 
C9ORF72 gene in the SH-SY5Y luciferase reporter cell 
lines.
PFI‑1 mediates an increased expression of three transcript 
variants of the human mutant C9ORF72 gene in C9BAC 
primary cortical cultures
To further evaluate the effects of the BETi PFI-1 in a 
more complex and physiologically relevant ex vivo model 
of C9ORF72, we analyzed primary cortical cultures 
derived from a C9ALS/FTD mouse model. We used the 
transgenic C9BAC mouse model carrying a BAC that 
contains a segment of a human C9ORF72 gene derived 
from a familial ALS/FTD patient [55]. As depicted sche-
matically in Fig. 2a, this construct (153.2 kb) contains the 
human C9ORF72 upstream and gene promoter regions 
(140.5 kb), exons 1 to 6 and a ~ 500 G4C2 hexanucleotide 
repeat expansions within intron 1. In this C9BAC mice, 
the truncated human C9ORF72 gene can generate the 
three transcript variants V1, V2 and V3 (as well as Vall) 
in all tissues examined, including the cortex [55]. Pri-
mary cortical cells derived from neonatal C9BAC mice 
were grown in culture for 9 days in vitro (DIV) and then 
treated for 24 h with either 0.05% DMSO alone (Control) 
or with 5 μM PFI-1 in 0.05% DMSO (PFI-1). At 10 DIV, 
these cortical cultures were processed to evaluate the 
presence of C9ORF72 transcripts (Fig. 2), poly(GP)-DPRs 
(Fig. 3) and RNA foci (Fig. 4). Of note, neither treatment 
with PFI-1 nor with DMSO caused any detectable neu-
ronal toxicity (see for example images Fig. 3).
Fig. 2 The bromodomain inhibitor PFI-1 enhances the expression of the C9ORF72 transcript variants. a Schematic representation of the BAC 
construct (153.2 kb) containing the human C9ORF72 gene promoter region (140.5 kb), exons 1 to 6 and a ~ 500 G4C2 hexanucleotide repeat 
expansions within intron 1 (red hexagons). The regions where each TaqMan probe hybridizes to detect the transcript variants V1 (blue), V2 (purple), 
V3 (orange) and Vall (green) are indicated. b–e TaqMan-based expression analyses of the V1 (b), V2 (c), V3 (d) and Vall (e) C9ORF72 transcripts. 
Samples were obtained from 10 DIV C9BAC primary cortical cultures treated with PFI-1 (5 µM in 0.05% DMSO) or vehicle DMSO (0.05%) for 24 h. 
Expression of each C9ORF72 transcript was normalized to DMSO treatments, and internally normalized to the expression of house-keeping gene 
Hprt. In all graphs, bars represent mean ± S.E.M. *P < 0.05, **P < 0.01 and ***P < 0.001 relative DMSO treated cells, unpaired Student’s t-test (n = 3 
independent experiments)
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Detection of the human C9ORF72 transcript vari-
ants V1, V2 and V3, as well as all variants (Vall) in the 
C9BAC cultures, was performed by TaqMan qRT-PCR 
using human-specific probes. Treatment of C9BAC neu-
rons with PFI-1 significantly increased levels of human 
C9ORF72 V1, V2, V3 and Vall mRNAs, compared to 
DMSO alone (Fig.  2b–d). This finding is in agreement 
with our results in the C9ORF72 SH-SY5Y LE90 and SH-
SY5Y LE200 cell lines (Fig. 1c; Additional file 1: Fig. S1C) 
and show that the BETi PFI-1 enhances the expression of 
the human mutant C9ORF72 gene in C9BAC neurons.
PFI‑1 treatment reduces poly(GP)‑DPR inclusions in C9BAC 
primary cortical neurons
Accumulation of DPRs represents a key pathological 
hallmark of C9ORF72 expansion carriers. Sense and anti-
sense C9ORF72 transcripts are translated into five dif-
ferent DPR proteins by RAN translation [17] and form 
neuronal inclusions in the brains of C9ALS/FTD patients 
[18–21]. Among the five DPRs produced from the sense 
(G4C2) and antisense (G2C4) transcripts, the RAN trans-
lation product poly(GP) is readily detected throughout 
the brain of adult C9BAC mice as well as in 10 DIV pri-
mary cortical neurons derived from these mice at neona-
tal stages [55]. Accordingly, double immunofluorescence 
staining with a well-characterized anti-poly(GP) antibody 
[18, 55] and an anti-MAP2 antibody revealed robust 
poly(GP)-DPR protein inclusions in 10 DIV primary cor-
tical neurons derived from C9BAC mice, but not from 
non-transgenic wild-type mice littermates (termed Ntg) 
(Fig. 3a). These poly(GP) inclusions were detected most 
frequently in the nucleus (indicated by co-localization 
with DAPI staining), although some cytoplasmic inclu-
sions were also observed. To confirm the specificity of 
the anti-poly(GP) antibody in our cultures, the antibody 
was pre-incubated with an excess of poly(GP) peptide 
before performing the immunostaining assays in the 
C9BAC neurons. This pre-absorption step prevented the 
detection of the endogenous poly(GP) signal in C9BAC 
neurons, thereby confirming the specificity of our anti-
poly(GP) antibody-dependent detection of poly(GP) in 
our in vitro C9ORF72 model (Fig. 3a, right column). We 
next evaluated whether the PFI-1 treatment reduced the 
poly(GP) inclusions in C9BAC neurons. As shown by 
representative confocal images (Fig. 3a) and signal quan-
tifications (Fig.  3b), PFI-1 treatment led to a significant 
reduction in the intensity of the poly(GP) nuclear signals 
in C9BAC cortical neurons. The poly(GP) nuclear signals 
Fig. 3 PFI-1 treatments reduce poly(GP) levels in C9BAC primary cortical neurons. a Representative confocal images of fixed 10 DIV cortical 
neurons derived from C9BAC (C9BAC) and non-transgenic (Ntg) mice analyzed by immunofluorescence labeling with an antibody against MAP2 
(red) to identify neurons and an antibody against poly(GP) (green) to identify poly(GP) DPRs. DAPI (blue) staining identified the nuclei. Images 
show abundant presence of poly(GP) DPRs in C9BAC, but not in Ntg, cortical neurons. Poly(GP) DPRs are strongly reduced after treatment with 
PFI-1 (5 µM in 0.05% DMSO). Pre-incubation of the anti-poly(GP) antibody with a poly(GP) peptide led to a significant loss of the Poly(GP)-DPR 
signal. b Quantification of the nuclear fluorescence intensity at each indicated condition, normalized to the intensity in Ntg cells. Bars represent 
mean ± S.E.M. ***P < 0.001 relative to untreated C9BAC cells, one-way ANOVA. (n = 3 independent experiments with a minimum of 30 nuclei 
quantified for each condition)
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were found unchanged in neurons treated with the vehi-
cle DMSO (Fig. 3a, b). Together, our in vitro data demon-
strate that a treatment of C9BAC cortical neurons with 
BETi PFI-1 reduces poly(GP)-DPR inclusions.
PFI‑1 treatment increases intranuclear RNA foci in C9BAC 
primary cortical neurons
The accumulation of repeat transcripts in intranuclear 
RNA inclusions is another key molecular hallmark of 
C9ORF72 expansion carriers; however, whether RNA 
foci are toxic [11] or neuroprotective under certain 
Fig. 4 The bromodomain inhibitor PFI-1 increases sense RNA foci in C9BAC primary cortical neurons. a Representative confocal images (upper 
row) of fixed 10 DIV cortical neurons derived from C9BAC (C9BAC) and non-transgenic (Ntg) mice analyzed by RNA FISH using a 5′Cy3-tagged 
G2C4 DNA probe (red) targeting the sense C9ORF72 repeat transcripts. Samples were also stained with DAPI (blue) to visualize the nucleus (blue). 
Black-and-white inverted images (lower row) are depicted to optimize visualization of the RNA foci. Brightfield microscopy was used to identify 
neurons from glial cells (not shown). Images show the presence of sense RNA foci in C9BAC (but not in Ntg) cortical neurons, that are increased 
in number after treatment with PFI-1 (5 µM in 0.05% DMSO) for 24 h. No RNA foci are detected after RNAse treatment. b Quantification of RNA 
foci in the different conditions as indicated. Evaluated nuclei were separated in populations of > 10 or ≤ 10 sense RNA foci. Bars show the mean 
percentage ± S.E.M. of each population with respect to total quantified nuclei in each condition. ***P < 0.001 relative to untreated C9BAC cells, 
one-way ANOVA (n = 3 independent experiments with a minimum of 30 nuclei quantified for each condition)
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circumstances is unclear [26, 27]. Accumulation of 
both sense (G4C2) and antisense (C2G4) repeat tran-
scripts at intranuclear RNA foci represents a hallmark 
of C9ORF72 expansion carriers [19, 22–25]. C9BAC 
mice recapitulates this pattern showing intranuclear 
sense (and to lesser extent antisense) RNA inclusions 
throughout the mature brain (10 and 24-month-old). 
Thus, one to five sense foci are detected by RNA fluo-
rescence in situ hybridization (FISH) in the majority of 
foci-positive nuclei of the cortical internal pyramidal 
layer (layer V) [55]. RNA FISH coupled with cell-type-
specific immunostaining has further revealed G4C2 
sense RNA foci in C9BAC neurons as well as in astro-
cytes [55]. To investigate whether PFI-1 treatment can 
reduce RNA foci in cultured C9BAC neurons, we first 
determined that this hallmark can be also detected 
in 10 DIV primary cortical cultures derived from 
neonatal C9BAC mice. For this, we used FISH with 
a 5′Cy3-tagged G2C4 DNA probe against the sense 
repeat expansion of C9ORF72 transcripts, together 
with DAPI staining to visualize the nucleus (Fig.  4a, 
upper images). To optimize FISH visualization, confo-
cal images are also shown as black-and-white inverted 
images (Fig.  4a, lower images). To concentrate our 
analysis in the FISH signal coming from the neurons, 
avoiding glial cells, confocal microscopy was com-
bined with brightfield microscopy to further expose 
the structure of cells (not shown). As shown in repre-
sentative confocal images, untreated primary cortical 
neurons derived from C9BAC mice exhibited sense 
RNA foci in their nuclei (Fig.  4a). These RNA foci 
signals were detected in the vast majority (> 95%) of 
the C9BAC neurons (data not shown), were lost fol-
lowing RNAse treatment and were absent in neurons 
obtained from non-transgenic littermates  (Fig.  4a). 
Quantification of the number of these sense RNA foci 
in untreated C9BAC neurons revealed that 50% con-
tained one to ten detectable foci (≤ 10), while the other 
50% contained more than ten detectable foci (> 10) 
(Fig.  4b). Treatment of the cultures with DMSO did 
not significantly alter this proportion (Fig.  4a, b). By 
contrast, confocal image analysis (Fig.  4a) and subse-
quent quantification (Fig.  4b) revealed that treatment 
of the C9BAC cultures with PFI-1 led to an increase 
in the number of intranuclear foci in C9BAC neurons. 
PFI-1 induced a significant increase in the numbers 
of nuclei containing > 10 foci, paralleled by a signifi-
cant reduction in the number of nuclei containing ≤ 10 
foci. Together these results indicate that treatment of 
C9BAC cortical neurons with BETi PFI-1 leads to an 
enrichment of intranuclear RNA foci.
JQ1 treatment reverts spatial memory impairment 
of C9BAC mice
Previous reports demonstrate that the C9BAC mouse 
model does not exhibit the robust behavioral defects 
that are characteristic of ALS (i.e. motor deficits) or FTD 
(i.e. social interaction) [55]. Nevertheless, 6-month-old 
C9BAC mice show mild hippocampal-dependent spa-
tial memory deficits, as measured by the object loca-
tion memory (OLM) task [61]. In this simple single-trial 
behavioral memory task [62, 63], which relies on the 
rodent’s innate preference for novelty and require the 
hippocampus, animals are presented with a non-dis-
placed (ND) versus displaced (D) object 24 h after train-
ing, while free exploring is allowed (avoiding stress) 
(Fig. 5a). In agreement with previous studies [61], it was 
found that 6-month-old C9BAC mice performed poorly 
on the OLM test, displaying limited exploration of the 
displaced object relative to control mice (Fig.  5b–d). 
To evaluate the effect of BETi in these animals we used 
JQ1, which exhibits comparable ability to stimulate the 
human C9ORF72 gene expression than that shown by 
PFI-1 (Fig. 1). Previous studies performed a pharmacoki-
netic analysis of JQ1 in plasma, testis and brain follow-
ing a 7-day treatment (i.p. 0.5  mg/kg/day for 7  days) in 
adult mice; it was determined that JQ1 is well tolerated, 
efficiently crosses the blood–brain barrier and remains 
bioavailable in brain tissue [64, 65]. Here, using the same 
application type, dose and schedule (i.p. 0.5  mg/kg/day 
for 7 days), we also found that treatment of 6-month-old 
C9BAC mice with JQ1 was well tolerated and did not led 
to any apparent toxicity or aberrant phenotypical altera-
tions, including changes of total exploration time in the 
OLM test (Fig.  5e). Strikingly, all C9BAC mice showed 
significant improvements in the OLM task after 7  days 
of JQ1 treatment (Fig. 5b–d). This was especially evident 
when we displayed the increased normalized exploration 
time towards the displaced object for each individual ani-
mal before and after JQ1 treatment (Fig.  5c). Together, 
these results demonstrate that treatment with BETi 
JQ1can revert the hippocampal-dependent spatial mem-
ory impairment of C9BAC mice.
Discussion
Using C9ALS/FTD luciferase reporter cell lines generated 
by our team and comprising the human C9ORF72 gene 
with pathological G4C2 repeat expansions, we assessed 
whether a specific set of small molecules targeting and 
inhibiting chromatin-regulating proteins can modulate 
C9ORF72 gene expression. Of the 14 different epidrugs 
tested, bromodomains inhibitors consistently increased 
C9ORF72 transcription in the C9ALS/FTD luciferase 
reporter cell lines. Using primary cortical cultures from 
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C9BAC mice, we further showed that treatment with 
the BETi PFI-1 results in (1) increased expression of 3 
human mutant C9ORF72 transcript variants (V1-V3), (2) 
reduced presence of poly(GP)-DPR inclusions, and (3) 
increased accumulation of intranuclear RNA foci. Stud-
ies in  vivo further demonstrated that administration of 
the BETi JQ1 rescued hippocampal-dependent cognitive 
impairments in C9BAC mice. The data is summarized in 
Fig. 5 Treatment with JQ1 reverses spatial memory impairment in 6-month-old C9BAC mice. a Schematic representation of the object location 
memory (OLM) task, in which mice were subjected to habituation, followed by exposure to two similar objects (“Training”). Twenty-four h later 
(“Test”) the animals were evaluated by re-exposure for 10 min to the same testing area with one non-displaced object (ND) and one displaced 
object (D). b Quantification shows normalized exploration time in seconds of individual 6-month-old male C9BAC and Ntg mice, before and after 
JQ1 treatment (i.p. 0.5 mg/kg/day for 7 days), with non-displaced (ND) versus displaced (D) objects. c Graph shows normalized exploration time in 
seconds (s) of C9BAC mice before and after JQ1 treatment. d Discrimination index shows the time spent in exploring the displaced object (D) over 
the total time exploring both objects (N + D). An index of > 0.5 indicates that mice can positively discriminate between the D and ND object. The 
data shows that treatment of C9BAC mice with JQ1 for 7 days rescues their OLM impairment, reaching spatial memory levels comparable to Ntg 
mice. e Graph shows total exploration time and indicates that C9BAC and Ntg mice have the same exploration capacity and that JQ1 treatment 
does not alter this. Bars represent means ± SEM. Statistical analysis was performed by one-way ANOVA. *P < 0.05 and **P < 0.01 relative to untreated 
C9BAC
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a model (Fig.  6). Our findings place BETi as a potential 
therapy for C9ALS/FTD by ameliorating C9ORF72-asso-
ciated pathological and behavioral abnormalities.
Our data indicate that BETi PFI-1 treatment rescues 
both haploinsufficiency and DPR-mediated toxicity 
in C9BAC neurons. Currently, there are two principal 
explanations for how PFI-1 treatment could reduce DPRs 
through increasing C9ORF72 gene expression. First, PFI-
1-mediated increases in C9ORF72 mRNA and hence 
protein levels can maintain the autophagy capacity suf-
ficiently high to degrade poly(GP)-DPRs in C9BAC neu-
rons. This mechanism is supported by recent studies 
demonstrating that reduced C9ORF72 protein levels 
lead to autophagy deficits and consequently impaired 
Fig. 6 Proposed model describing the effects of BETi PFI-1 and JQ1 in C9BAC cultures and mice. PFI-1 and JQ1 are highly potent pan-BETi and 
antagonize BET family members BRD4 > BRD2/3 > BRDT. a Treatment of primary cortical cultures from C9BAC mice with PFI-1 (5 μM for 24 h) 
enhances the expression of the human C9ORF72 gene in neurons, leading to increases in C9ORF72 transcripts, reduction in poly(GP) aggregates, 
and accumulation of RNA foci. The methylation of the human C9ORF72 gene promoter region represents an enrichment of several repressive 
histone modifications, including H3K9me3 and H3K27me3 in the histone tails of the depicted nucleosomes. Higher-order DNA structures, called 
G-quadruplexes, found in the G4C2 hexanucleotide repeat expansions (HRE) of the C9ORF72 gene body are also shown. For simplicity only BET 
family member BRD4 is shown and the ET domain omitted. b Treatment of 6-month-old C9BAC mice with JQ1 (i.p. 0.5 mg/kg/day for 7 days) 
rescues hippocampal-dependent cognitive spatial memory, as measured by the object location memory (OLM) task
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clearance of DPRs [14, 54]. Second, PFI-1-mediated 
increases in intronic repeat transcripts may consequently 
lead to more RNA foci that, in turn, prevent produc-
tion of toxic DPRs in the cytoplasm. RNA foci have been 
mainly classified as neuropathological hallmarks, as they 
are proposed to sequester RNA-binding proteins and 
splicing factors, including RanGap1, ADARB2, nucleo-
lin, hnRNP-H, hnRNPA1, hnRNPA3, ASF/SF2, Pur-α, 
Zfp106, SRSF2, ALYREF and hnRNP H1/F [11]. How-
ever, several studies in humans and flies indicate that 
nuclear RNA foci by themselves are not toxic. Thus, a 
correlation study in a large cohort of C9ORF72 expan-
sion carriers found that the abundance of antisense RNA 
foci in the frontal cortex was associated with a delayed 
age of disease onset [24]. And intriguingly, two genetic 
studies using sense transcript (antisense was not tested) 
in Drosophila distinguished the toxicity from repeat 
RNA as compared to the DPR protein [26, 27]. These 
studies reported that while  polyA+ transcripts encoding 
DPRs cause robust neurodegeneration, neuronal survival 
was intact when cells expressed repeat transcripts that 
could not produce DPRs [26]. Another study expressing 
expanded  G4C2 repeats in an intron  resulted in the accu-
mulation of numerous nuclear RNA foci but with no or 
little global effects on RNA processing and cellular tox-
icity [27], suggesting that, at least in Drosophila, nuclear 
RNA foci sequesters repeat transcripts, hence prevent-
ing their transport to the cytoplasm and the subsequent 
production of toxic DPRs. Based on these findings, we 
propose that the increased intranuclear RNA foci in 
PFI-1 treated C9BAC cortical neurons could function 
as a neuroprotective sponge for pathological C9ORF72 
repeat transcripts and hence impede the generation of 
toxic poly(GP)-DPR inclusions. It is currently not known 
if both sense and antisense repeat transcripts could give 
rise to beneficial effects. In the case of C9BAC neurons, 
poly(GP)-DPRs are abundant and are produced from the 
sense (G4C2) and antisense (G2C4) transcripts.
All 6 bromodomain inhibitors evaluated in our epid-
rug screen significantly increased C9ORF72 transcrip-
tion in the pathological G4C2 repeat expansions (90 
and/or 200 HRE). Bromodomain-containing proteins 
belong to an evolutionarily conserved family encom-
passing approximately 61 types of domains in humans; 
these domains are present in 46 different proteins, some 
of them containing up to 6 bromodomains [66, 67]. In 
general, bromodomains are divided into 8 sub-families 
(I-VIII) based on sequence and structural conserva-
tion [60, 68, 69]. One of these families, bromodomain 
family II, or also named the BET bromodomain fam-
ily, shares a common domain architecture comprising a 
pair of N-terminal bromodomains (BDs: BD1 and BD2) 
and an extra-terminal (ET) domain [67]. Importantly, 
five of the six bromodomain inhibitors—PFI-1, JQ1, 
RVX-208, I-BET151 and OTX015—that were found 
here to increase C9ORF72 gene expression are selec-
tive and potent inhibitors of this BET bromodomain 
family [59, 60]. Our results extend a previous study by 
Zeier et al. [42], that initially proposed BET and other 
bromodomain inhibitors as regulators of the C9ORF72 
locus in C9ALS. That study, which was focused on the 
effect of JQ1 and I-BET151 (and did not include PFI-
1), concluded that these compounds can substantially 
increase C9ORF72 gene expression (8–tenfold) in 
fibroblasts derived from C9ALS patients. Treatment of 
iPSC-derived motoneurons from C9ALS patients with 
JQ1 and I-BET151 showed a rather modest effect on 
C9ORF72 gene expression (1.3–3 fold) [42].
The BET family consists of four conserved mammalian 
members, namely, BRD2, BRD3, BRD4 and testis-spe-
cific BRDT. While PFI-1 and JQ1 are structurally dif-
ferent, both are highly potent pan-BETi and antagonize 
BRD4 > BRD2/3 > BRDT [60, 67]. BET proteins, acting 
through BD1 and BD2, recognize (or ‘read’) acetylated 
lysines (Kac) in the tails of the four histone proteins and 
in non-histone proteins, including transcription factors 
[66, 67, 70]. Furthermore, the ET domain of BET proteins 
mediates protein–protein interactions and recruits tran-
scriptional and epigenetic regulatory complexes to the 
acetylated protein target, contributing to processes such 
as chromatin remodeling and transcription [66, 67]. BETi 
disrupt the BET-Kac interaction, leading to the release of 
BET proteins from the chromatin. In general, BETi result 
in global and specific transcriptional repression, particu-
larly of oncogenes, and hence BETi have been used in 
over 20 clinical trials for cancer [67, 71]. Other studies, 
however, have reported that subsets of genes  are upreg-
ulated by BETi [68, 72–75]. The mechanisms underly-
ing this locus-specific up-regulation or de-repression of 
transcription by BETi are not well understood, in part 
because the comprehension of the BET protein complex 
formation at target genes is still limited [67]. Recently, 
the interactome of each BET protein (BRD2-4 and BRD-
T) was established using proteomic analyses in cell lines 
(HEK293 cells and chronic myeloid leukemia K652 cells) 
in the presence or absence JQ1 [70]. In the absence of 
JQ1, 650 high-confidence BET interactors were identi-
fied and enriched interactomes generated for each BET 
protein, among them not only transcriptional activators, 
such as the Positive Transcription Elongation Factor b 
(P-TEFb), but also transcriptional repressors including 
the Negative Elongation Factor b (NELFb) [70]. Interest-
ingly, NELFb has been shown recently to play a relevant 
role in constraining transcription as it mediates RNA 
polymerase II pausing at proximal gene promoter regions 
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[76]. Hence, release of NELFb from these promoters is 
strongly associated with transcriptional enhancement.
JQ1 treatment induced extensive changes in the BET 
interactome, which now include novel Kac-independent 
interactions with components of the transcription ini-
tiation complex (PIC) like Mediator, TFIID, TFIIH, and 
RNAPII [70]. Future studies in C9ALS/FTD neurons will 
be needed to address whether BETi induce de-repression 
of the silent expanded C9ORF72 gene by promoting the 
release of repressors, stimulating the interaction with 
specific activators, or both. Additionally, it is important 
to consider that BETi may be increasing the expression of 
the mutant C9ORF72 gene indirectly, perhaps by altering 
the expression of upstream regulators of this gene. BETi 
may also restore transcriptional and epigenetic altera-
tions observed in C9ALS/FTD patients and model sys-
tems, including widespread changes in mRNA expression 
[46, 77, 78] and global loss of the repressive H3K9me3 
mark in several brain regions, including in the spinal 
cord, motor cortex and hippocampus [61].
Our studies in  vivo demonstrate that BETi JQ1 
improves the object location preference (OLM) in 
C9BAC mice, indicating that this epidrug can rescue, at 
least in part, hippocampal-dependent cognitive deficits 
in spatial learning and memory found in C9BAC mice. In 
contrast, a comparable JQ1 treatment in wild-type mice 
showed that this BETi can block novel object preference 
(NOR) [65], a task that studies non-spatial learning of 
object identity and relies on multiple brain regions, with 
some controversy on the involvement of the hippocam-
pus [62]. Together, these data suggest that the role of BET 
proteins in non-spatial long-term memory formation is 
likely associated with a variety of brain regions whose 
precise roles in hippocampal function are not well under-
stood. It will be interesting to evaluate if JQ1 treatment 
in C9BAC mice increases the expression of C9ORF72 
transcripts (testing both the human mutant C9ORF72 
gene and the mouse wild-type C9orf72 gene), reduces 
poly(GP)-DPR inclusions and enhances intranuclear 
RNA foci. Similar studies with PFI-1 could be undertaken 
although such preclinical animal research should be 
accompanied by pharmacokinetic analysis of this epidrug 
in the brain, as shown for JQ1 [64].
While there is a risk that using JQ1 or equivalent BETi 
to treat systemic diseases (e.g. several types of cancer) 
may negatively affect cognition in normal subjects, our 
data nonetheless supports a potential use of JQ1-like 
epidrugs as a therapeutic strategy in C9ALS/FTD. In 
the future, it will be important to evaluate whether any 
additional behavioral abnormality found in C9ALS/
FTD patients (mostly absent in mouse models), includ-
ing hyperactivity, anxiety, antisocial behavior, and motor 
deficits, may be also ameriolated by BETi treatment.
Methods
Animals
All protocols involving mice were carried out according 
to NIH, ARRIVE and ANID/CONICYT guidelines and 
were approved by the Ethical and Bio-security Commit-
tees of Universidad Andrés Bello. C9BAC mice express-
ing C9ORF72 genomic DNA sequence derived from a 
familial C9ALS/FTD patient under a B6SJLF/J back-
ground were used together with the non-transgenic 
littermates (Ntg) as controls [55]. Transgenes in the 
C9BAC mice were identified by PCR using the primers 
for Orf72e3: forward 5′ TTA ATT TCC TAC CCC TGC 
CC 3′; reverse 5′ AGG CCT TGA CAA ATG TAG CC 3′ 
and for Mm10chr3: forward 5′GCC TCA CCt CCT AAG 
AGC CTA 3′; reverse 5′ CCT TTG TGT CAC ACG GAT 
ATC 3′ [55].
Generation of SH‑SY5Y G4C2 cell lines
Three different stable SH-SY5Y cell lines were gener-
ated based a construct of the human C9ORF72 gene 
that included 4 kb of the promoter region and exons 1a 
through 2 with 10, 90 or 200 hexanucleotide expansions. 
This was cloned into the PGL4.17[luc2/Neo] plasmid 
(Promega), in which expression of luciferase is driven by 
the C9ORF72 promoter with the associated G4C2 repeat. 
Plasmids were transfected into SH-SY5Y cells and sta-
ble lines were selected using G418 (Gibco). These were 
designated SH-SY5Y WT, SH-SY5Y LE90 and SH-SY5Y 
LE200, respectively designating the G4C2 repeat motif 
sizes (10, 90 and 200).
SH‑SY5Y G4C2 cell line maintenance and epidrug 
treatment
Cells were cultured in DMEM-F12 (Gibco, 12,400–024) 
10% FBS (HyClone, SH30071.03) and were selected by 
adding G418 to culture medium (HyClone, SV30068.02). 
When SH-SY5Y G4C2 cell lines reached 80% confluence 
they were treated for 24  h with 14 different epidrugs: 
details on the company, lot number and concentrations 
of each epidrug used to treat SH-SY5Y cells are shown 
in Additional file  1: Table  S1. All epidrugs were freshly 
prepared and dissolved in DMSO (Sigma, D2650-5) 
and then diluted in sterile ultrapure water (Invitrogen, 
10,977–023) before using them in cultures. The DMSO 
volume concentrations (v/v) used was dependent on the 
final epidrug concentration: 0.005% DMSO for 0.5  µM 
(only for GSK3430), 0.025% DMSO for 2.5 µM (only for 
OTX015), 0.25% DMSO for 25  µM (only for RXV208) 
and 0.05% DMSO for 5 µM (rest epidrugs). After the 24 h 
treatment, cells were harvested following the instruc-
tions of Dual-Luciferase® Reporter Assay System Kit 
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(Promega, E1960). Relative light units were normalized 
to total protein levels and quantified with Pierce BCA 
Protein Assay kit (Thermo Fisher Scientific, 23255).
Primary C9BAC cortical neuronal cultures
Prior to preparing the primary cultures (2.5  h before), 
a small tail tissue sample of each P0-2 mouse was per-
formed to identify transgenic C9BAC mice from their 
non-transgenic littermates by PCR (see above for prim-
ers; for quick DNA purification see [79]. Cerebral corti-
cal cultures were generated as previously described [80] 
with some modifications. Briefly, cortices from individual 
brains of C9BAC mice were placed into ice-cold PBS 
0.01 M (Gibco, Cat. No. 14185–052) containing 50 μg/ml 
penicillin/streptomycin (Gibco, Cat. No. 15070–063) and 
dissected into small pieces. Cortical tissue (one cortex for 
one 24-well plate) was digested in 2 ml PBS 0.01 M con-
taining 50U of papain (Worthington, Cat. No. LS03126), 
17 μg/μl L-Cysteine (Sigma, Cat. No. C7755) and 25 μl/
ml DNAase (Roche, Cat. No. 1010415900) at 37  °C for 
15 min. Cells were transferred to a 15 ml tube containing 
Neurobasal Medium (Gibco 21103-049), 1% penicillin–
streptomycin (Gibco, Cat. No. 15070-063) and 2-Amino-
5-phosphonopentanoic acid (5  mM; Sigma, Cat. No. 
A5284), re-suspended by mechanical agitation through 
fire-polished glass Pasteur pipettes of different tip diam-
eters, and counted: 250,000  cells/well were plated on 
poly-L-lysine-coated 24-well plates (1  mg/ml; 30,000–
70,000 MW; Sigma, Cat. No. P2636). Each well contained 
Neurobasal Medium (Gibco, 21103-049) supplemented 
with B27 (Gibco, 17504-044) and 0.5 × GlutaMax (Gibco, 
3505006) in the presence of 100 μg/ml Primocin (Invivo-
Gen, Cat. No. ANT-PM-1). One day after plating, cells 
were treated during 24  h for once with 20  μM cytosine 
arabinoside in order to prevent microglial proliferation. 
After that, all media was changed. Half of the media was 
replaced every 2–3 days. Treatments with PFI-1 (5 μM) 
were performed at 9 DIV for 24 h.
TaqMan qRT‑PCR
Total RNA was extracted from 10 DIV primary C9BAC 
and non-transgenic cortical cells (2 million/condi-
tion) using Trizol (Thermo Fisher Scientific, 15596018) 
following manufacturer instructions. Reverse tran-
scription to cDNA was performed with High-Capac-
ity RNA-to-cDNA™ Kit (Thermo Fisher Scientific, 
4387406). Quantitative PCR was performed using 
TaqMan Fast Advanced Master Mix following manu-
facturer instructions. Every transcript variant of the 
human C9ORF72 gene were measured with a spe-
cific probe for each variant (V1, V2 and V3) and one 
probe that hybridizes with all variants (Vall) (Thermo 
Fisher Scientific). As an endogenous control we used 
a mouse Hprt commercial assay (Thermo Fisher Sci-
entific, Mm01545399_m1). The obtained results were 
processed by using the delta delta Ct method. Details 
about the different probes are depicted in Additional 
file 1: Table S2.
Poly(GP) immunostaining
Immunostaining to detect poly(GP) dipeptides on 
C9BAC cortical neurons as previously described [18]. 
Briefly, primary C9BAC and non-transgenic corti-
cal cells (10 DIV) were fixed with PFA 4% and sucrose 
4%, and then permeabilized with Triton X-100 (Sigma, 
T8787) 0.1% v/v for 20  min. Next, cells were blocked 
with Serum-Free Protein Blocking solution (DAKO, 
X0909) for 30 min before primary antibody incubation. 
Poly(GP) was detected with anti-poly(GP) polyclonal 
antibody (1:20.000, Merck, ABN455) and neurons 
were labeled with anti-microtubule associated pro-
tein 2 monoclonal antibody (MAP2 1:200; Santa Cruz, 
sc-74421); primary antibodies were incubated over-
night at 4ºC. Secondary antibody incubations were 
performed for 2  h using Alexa 488 (1:500, Company, 
A11034) to detect poly(GP) and Alexa 546 for MAP2 
(1:500, Company, A11003). Coverslips were mounted 
using Prolong® Gold antifade reagent with DAPI 
(Thermo Fisher Scientific, P36931).
Images of primary cortical neuron cultures were 
taken on an Olympus FV1000  confocal microscope 
with a 60 × oil objective (NA = 1.35;  UPLS APO)  and a 
z-step of  0.5  μm optical sections (velocity scan 12.5  μs/
per pixel; resolution 1024 × 1024 pixels, equivalent to 
212  μm × 212  μm).  The following laser wavelengths 
were used to detect DAPI  (Ex 405  nm and Em 422–
475 nm), MAP2-Alexa546  (Ex 543 nm and Em BA560–
660  nm)  and poly(GP)-Alexa488 (Ex 488  nm and Em 
500–530  nm).  Maximum intensity projections of  con-
focal z-stack  images of whole nuclei (containing 8–10 
stacks) were analyzed.  To validate the specificity of the 
anti-poly(GP) antibody, customized synthesis of puri-
fied poly(GP)8 dipeptide was obtained from Abmgood. 
For the pre-absorption assay, the anti-poly(GP) anti-
body was pre-incubated (30  min at room temperature) 
with an excess of the poly(GP)8 peptide in Serum-Free 
Protein Blocking solution (DAKO, X0909) before per-
forming the immunostaining assays as described above. 
Fiji ImageJ software (8 bits, measuring intensity from 0 
to 150) was used to measure the poly(GP) nuclear fluo-
rescence intensity. Line scans were drawn in ImageJ to 
quantify the relative intensities of the fluorescence signal 
for poly(GP). Maximum intensity projections of confocal 
z-stack images of whole nuclei were analyzed. At least 30 
neuronal nuclei were analyzed for each condition.
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RNA fluorescence in situ hybridization (FISH)
RNA FISH with a probe targeting C9ORF72 sense tran-
script on primary C9BAC neurons was performed as 
previously described [55]. Briefly, primary C9BAC and 
non-transgenic cortical cells (10 DIV) were fixed with 
PFA 4% and then permeabilized with Triton X-100 
(Sigma, T8787) 0,1% v/v for 20  min. Next, cells were 
incubated for 1 h with pre-hybridization buffer followed 
by overnight hybridization at 55ºC with a DNA probe 
targeting C9ORF72 sense transcript coupled with a Cy3 
5′ end tag ((/5Cy3/-GGC CCC )4, IDT 162,193,262). 
Coverslips were mounted using Prolong® Gold antifade 
reagent with DAPI (Thermo Fisher Scientific, P36931). 
Images of primary cortical neuron cultures were 
taken on a Leica TCS SP8 confocal microscope with a 
63 × oil objective and × 4 × digital zoom (NA = 1.4; HC 
PL APO CS2)  and a z-step of  0.5  μm optical sections 
(velocity scan 600  Hz; resolution 1024 × 1024 pixels, 
equivalent to 46.18 μm × 46.18 μm). The following laser 
wavelengths were used to detect DAPI (Ex: 405 nm and 
Em: 410–483 nm), RNA-foci were detected by Cy3 dye 
(TRITC,  Ex: 532  nm and Em: 580–625  nm). Bright-
field images were taken to identify cell body.  Maxi-
mum intensity projections of confocal z-stack images of 
whole nuclei (containing 10 stacks) were analyzed. Fiji 
ImageJ software (8 bits, measuring foci from 0 to 50) 
was used to quantify the number of RNA foci. The 
quantification of foci (≥ 0.20 μm) was carried out under 
threshold conditions using the analyze particle plugin. 
Maximum intensity projections of confocal z-stack 
images of whole nuclei were analyzed. At least a total 
of 30 neuronal nuclei were analyzed for each condition.
Object location memory (OLM) tests
The single trail OLM test was performed as previ-
ously described [61, 63]. Briefly, this test consists of 
three steps: habituation, a training session (10  min) 
and finally a test session (10 min) 24 h later. Mice were 
individually habituated in an apparatus that contained 
a cage inside of a soundproof chamber. In the train-
ing session, the cage contained two identical objects, 
termed “non-displaced objects” (ND). During the test 
session, one object was changed its place in the cham-
ber, termed “displaced object” (D). The exploration time 
was recorded and defined as the time that the animal 
spent sniffing or touching the object with the nose and/
or forepaws. The ‘discrimination index’ was calculated 
by the time spent in exploring the displaced object (D) 
over the total time exploring both objects (D + ND).
JQ1 injections
A group of 6-month-old male mice C9BAC mice were 
first subjected to the OLM test to show impaired spa-
tial memory. Then, the same group of mice were 
injected intraperitoneally with (+)-JQ1  (Sigma-
Aldrich,  SML1524), as described previously [64]. 
Briefly, JQ1 was dissolved in DMSO at 5  mg/ml and 
then diluted 1:10 in 10% (2-Hydroxypropyl)-b-cyclo-
dextrin (Sigma-Aldrich, H107). The mixture was 
injected i.p. into mice at a final concentration of 0.5 mg/
kg daily for 7 days in a row. Animals were weighed daily 
before injections  (ranging from 28 to 35  g) and fed 
ad libitum.
Statistical analyses
Statistical analyses were performed using GraphPad 
Prism 5 software. One-way ANOVA followed by the 
Bonferroni post-hoc was utilized when making multiple 
(three or more) comparisons. Unpaired Student’s t-test 
was performed when two populations were examined. In 
all figures, data is reported as mean ± S.E.M.; *P < 0.05, 
**P < 0.01 and ***P < 0.001 compared to controls, either 
wild-type or Ntg cells or DMSO-treated (as indicated). 
In some experiments (Fig. 1c, d), #P < 0.05, ##P < 0.01 and 
###P < 0.001 are shown to compare treated to untreated 
SH-SY5Y LE90/200 cells (as indicated in legends).
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